Alain Hendlisz

Scopus Publications

Deep epigastric lymph node involvement in patients with ovarian and colorectal peritoneal metastasis: A prospective pilot study
Antoine El Asmar, Charif Khaled, Isabelle Veys, Maria Galdon Gomez, Laurine Verset, Alain Hendlisz, Laura Polastro, Ana Veron Sanchez, Vincent Donckier, Gabriel Liberale
Surgery United States, 2026
Real-World Outcomes of [177Lu]Lu-DOTA-TATE Peptide Receptor Radionuclide Therapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors: Data from a Belgian ENETS Center of Excellence
I Lazarenko, M Mileva, R Manta, P Kristanto, A Hendlisz, J.-L. Van Laethem, Z Wimana, C Artigas, P Flamen, I Karfis
Acta Gastro Enterologica Belgica, 2026
Background and study aims: Peptide receptor radionuclide therapy (PRRT) has been reimbursed in Belgium since 2022. Post marketing monitoring of efficacy in Belgian context has not yet been performed. This study aimed to evaluate the efficacy and safety of PRRT in patients with progressive metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Patients and methods: Our retrospective analysis included GEP-NET patients who received at least one cycle of [177Lu] Lu-DOTA-TATE at Institute Jules Bordet (Brussels, Belgium) between 2013 and 2023. Treatment response was assessed according to RECIST 1.1 (Response Evaluation Criteria in Solid Tumors). Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier analysis. Treatment safety profiles were reported descriptively. Results: Following initial PRRT (PRRT-1), in 110 patients with progressive metastatic GEP-NETs (grades 1-3), median PFS was 22.5 months (95% CI: 19.7–29), and median OS was 42.3 months (95% CI: 34.3–55). RECIST 1.1 responses were complete response in 1%, partial response in 21.6%, stable disease in 60.8%, and progression in 16.7% of patients. Median time of follow-up post PRRT-1 was 26.4 months (range: 0.8 – 106.4). Grade 3-4 anemia, leukopenia, lymphopenia and thrombocytopenia occurred in 1.9%, 2.8%, 50.5% and 2.8% of patients, respectively. Two patients (1.8%) developed myelodysplastic syndrome. Grade 3 or 4 renal toxicity was observed in two patients who had impaired renal function prior to PRRT. Conclusion: Post-marketing analysis in an ENETS Center of Excellence confirmed that the efficacy and safety of PRRT in GEPNETs are consistent with phase 3 trial data.
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer
Ming Lei, Michael J. Overman, Jin Yao, Thierry André, Sara Lonardi, Heinz-Josef Lenz, Massimo Aglietta, Fabio Gelsomino, Ray McDermott, Ka Yeung Mark Wong, Michael A. Morse, Eric Van Cutsem, Alain Hendlisz, Dana B. Cardin, Bart Neyns, Andrew Hill, Anuradha Krishnamurthy, Franklin Chen, Samith Kochuparambil, Robert R. Jenq, Sandzhar Abdullaev, Beilei He, Ruslan Novosiadly, Scott Kopetz
Nature Communications, 2025
Nivolumab alone and in combination with ipilimumab demonstrated durable clinical benefit in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer in the phase 2 CheckMate 142 study. Here, we report exploratory biomarker analyses from CheckMate 142 evaluating associations between various tissue biomarkers and the efficacy of nivolumab monotherapy and nivolumab plus ipilimumab combination in these patients. Higher expression of inflammation-related gene expression signatures is associated with improved response per investigator assessment and survival benefit with nivolumab monotherapy. In contrast, higher tumor mutational burden, tumor indel burden, and degrees of microsatellite instability are associated with improved response per investigator assessment and survival benefit with nivolumab plus ipilimumab. While interpretation is limited by the exploratory nature of these analyses, they suggest that tumor antigenicity rather than baseline tumor inflammation might be important for the combinatorial efficacy. Validation of these findings in larger, randomized studies is necessary. In the CheckMate 142 study, nivolumab (anti-PD-1) alone and in combination with ipilimumab (anti-CTLA-4) was shown to induce durable clinical benefit in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Here, the authors perform exploratory biomarker analysis of the CheckMate 142 study.
Are epigenetic-targeting approaches ready for prime time in neuroendocrine neoplasms?
Michel Meyers, Ioannis Karfis, Alain Hendlisz
Current Opinion in Oncology, 2025
Purpose of review The purpose of this review is to evaluate the role of epigenetic-targeting approaches in the management of neuroendocrine neoplasms (NENs), particularly as a priming strategy for subsequent therapies. We explore the molecular basis of epigenetic modifications in NENs, and we review preclinical and clinical studies on DNA methyltransferase and histone deacetylase (HDAC) inhibitors. Recent findings DNA methyltransferase and HDAC inhibitors can upregulate SSTR2 expression, thereby improving radioligand uptake and treatment response in NENs. The LANTana study investigates ASTX727 as a strategy to restore SSTR2 expression in metastatic NENs, allowing previously ineligible patients to receive PRRT. Preclinical studies demonstrate that combining epigenetic agents with radiotherapy, chemotherapy, or targeted inhibitors can enhance tumour sensitivity and overcome resistance. Summary Epigenetic modifications play a crucial role in NENs, influencing tumour progression, therapy resistance, and SSTR2 expression. Epigenetic priming with DNA methyltransferase and HDAC inhibitors can enhance SSTR2 expression, improving the efficacy of PRRT in NENs. The LANTana study and other trials are investigating whether epigenetic-targeting approaches can be integrated into NEN treatment to optimize PRRT and overcome therapeutic limitations.
Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative
J. Taieb, J. Seligmann, D. Modest, C. Girault, F. Rivera, E. Mahillo, P. Osterlund, P. Pfeiffer, D. Malka, C. Louvet, A.R. Siebenhuner, C. Morf, C. de la Fouchardiere, L. Monard, M. Koopman, G. Vink, I. Borbath, L. Dewever, R. Adams, A. Reinacher-Schick, F. Pietrantonio, S. Lonardi, T. Aparicio, C. Cremolini, Pierre Laurent-Puig, David Tougeron, Côme Lepage, Aziz Zaanan, Jean Marc Phelip, Laetitia Dahan, Claire Gallois, Rosine Guimbaud, Véronique Vendrely, Christopher Jones, Christopher Williams, David Cairns, Nancy Fernandes Desilva, Karen Geboes, Sabine Tejpar, Veerle Casneuf, Leen Mortier, Jeroen Dekervel, Timon Vandamme, Anne Demols, Geneviève Van Ooteghem, Sofie Demeulder, Michèle Van Hooren, Francesco Sclafani, Marc Peeters, Jean-Louis Van Laethem, Marc Vanden Eynde, Eric Van Cutsem, Alain Hendlisz, Laura Delliponti, Federica Palermo, Lisa Salvatore, Monica Niger, Matteo Fassan, Lorenzo Fornaro, Massimo Di Maio, Florian Lordick, Dirk Arnold, Gunnar Folprecht, Arndt Vogel, Lukas Perkhofer, Alexander Stein, Peter Thuss-Patience, Volker Kunzmann, Thomas Ettrich, Annabel Alig, Ralf Hofheinz, Pompiliu Piso, Emmanouil Fokas, Enrique Aranda, Ana Fernandez Montes, Ramon Salazar, Elena Élez, Clara Montagut, Ángela Lamarca, Teresa Macarulla, Ruth Vera, Christophe Borg, Romain Cohen, Antony Turpin, Thierry Andre, Jean Baptiste Bachet, Pia Osterlund, Per Pfeiffer, Karen-Lise Garm Spindler, Tormod Guren, Marianne Guren, Christina Aasebo Overas, Julia Johansen, Inna Chen, Eetu Heervää, Bengt Glimelius, Arne Westgaar, Annika Ålgar, Benny Vittrup, Camilla Qvortrup, David Ljungman, Elin Kure, Bengt Gustafsson, Ellinor Bexe-Lindskog, Eva Serup Hansen, Eva Angenete, Gabor Istvan Liposits, Halfdan Sorbye, Helga Hagman, Inga Marie Loees, Jakob Eberhard, Jakob Hagen Vasehus Schou, Jan-Erik Frödin, Johan Haux, Kjell-Magne Tveit, Anders Jakobsen, Olav Dahl, Kjerstin Elvestaf Hestun, Line Tarpgaard, Mia Johansson, Niels Pallisgard, Pernille Holck Skov, Peter Nygren, Morten Braendengen, Ragnhild Loethe, Stine Winther, Svein Dueland, Torben Hansen, Sofia Heyman, Yvonne Wettergren, Emerik Osterlund, Oddmund Noordgard, Mats Perman, Jennie Aust, Sheraz Yaqub, Julian Hjamford, Jorgen Smeby, Kristoffer Lassen, Laurids Ostergard Poulsen, Maria Thomsen, Olav F. Dajani, Bard Rosok, Kristoffer Lassen, Kjetil Soreide, Anne Hansen Ree, Dieter Koberle, Thibaud Kossler, Sara De Dosso, Jeanine Roodhart, Miriam Chalabi, Remond Fijneman, Henk Verheul, Anna Tetering, Julien Edeline, Aurélien Lambert, Emmanuelle Samalin, Valérie Boige, Beata Juzyna
ESMO Open, 2025
This paper outlines proposals for the setup of a European Network for Gastro-Intestinal Cancers (ENGIC) initiative, aiming at promoting and fostering strategic academic clinical trials for gastrointestinal cancers in Europe. We discuss the presentation of the network, its main objectives, organization, internal/external processes, operational activities, governance and, finally, priority actions for the future. We propose that this provides a model that could be adopted by researchers working in other disease areas.
Development and Validation of an 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Imaging Score to Predict 12-Week Life Expectancy in Advanced Chemorefractory Colorectal Cancer
Zelda Paquier, Jennifer Dhont, Thomas Guiot, Hugo Levillain, Gabriela Critchi, Rita Saude Conde, Francesco Sclafani, Patrick Flamen, Nick Reynaert, Erwin Woff, Alain Hendlisz
JCO Clinical Cancer Informatics, 2025
PURPOSE Managing chemorefractory metastatic colorectal cancer (mCRC) requires a meticulous equilibrium between the efficacy and toxicity of interventions, a task compounded by the constrained life expectancy of the patient. While existing prognostic tools, such as the Colon Life nomogram, primarily focus on general patient conditions or a single diagnostic modality, they do not fully integrate the potential predictive value of multimodal data. This study aims to develop and validate an Imaging Score, integrating clinical and imaging features derived from whole-body 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography-computed tomography (PET-CT), predicting death probability within 12 weeks from treatment initiation for refractory disease. MATERIALS AND METHODS The development cohort comprises 254 patients from three clinical trials. Nine clinical variables and six imaging variables were assessed. After optimal subset selection through recursive Feature Elimination with cross-validation, a support vector classifier-trained machine learning model generated the Imaging Score. Validation was performed on a real-life patient cohort (n = 74). Model performance was assessed on discrimination (Harrell C-index) and calibration. RESULTS Final prognostic features included whole-body metabolically active tumor volume, Eastern Cooperative Oncology Group performance status, visceral fat density, number of metastatic sites, body mass index, maximum standardized distance, and months since diagnosis. The Imaging Score demonstrated robust discriminative ability in both the development (C-index, 0.797) and validation (C-index, 0.714) sets, outperforming the Colon Life nomogram that tended to overestimate 12-week mortality. CONCLUSION The Imaging Score, integrating 18 F-FDG PET-CT imaging with clinical parameters, is an effective prognostic tool for patients with chemorefractory mCRC. This combination of imaging biomarkers with clinical factors improves discrimination, enhancing its potential for clinical decision making, patient stratification for chemorefractory treatments, and trial eligibility.
Management of high-grade neuroendocrine neoplasms: impact of functional imaging
O Islam, K Sarti, L Verbruggen, V Vandersmissen, K Vanden Bulcke, L Annys, C Verslype, J L Van Laethem, H Rezaei Kalantari, J Janssens, A Hendlisz, P J Cuyle, G Demolin, J Decaestecker, K Geboes, J C Coche, J Van Ongeval, W Lybaert, M Peeters, I Borbath, T Vandamme
Endocrine Related Cancer, 2025
Gastroenteropancreatic neuroendocrine neoplasms (GEP NEN) exhibit substantial biological heterogeneity, impacting clinical management and outcomes. In 2019, the WHO subdivided the grade 3 (G3) neuroendocrine neoplasms (NEN) characterised by Ki-67 > 20% into the well-differentiated G3 neuroendocrine tumour (NET) and G3 poorly differentiated neuroendocrine carcinoma (NEC) subgroups. Since this update, questions about the prognostic implications and best treatment strategies for NET G3 and NEC remain. Therefore, we initiated a real-world retrospective observational cohort study using data from 225 NEC and 58 NET G3 patients treated in Belgium. Analysis of patient and tumour characteristics and the effect of survival was conducted. Most frequent primary locations were pancreatic (32.9%) and colorectal (21.5%), and 71.8% was diagnosed with stage IV disease. Median overall survival (mOS) was higher in NET G3 (41.3 months (m)) compared to NEC (13.2m). Of those who underwent functional imaging, fluorodeoxyglucose–positron emission tomography (18F-FDG-PET) imaging was positive in 90.6 and 95.6% of the NET G3 and NEC patients, respectively, and somatostatin receptor (SSTR) expression was seen in 97.4 and 66.0%, respectively. The latter was linked to better mOS, suggesting the added value of performing both SSTR imaging and 18F-FDG-PET for high-grade (HG) NEN to provide prognostic information and to possibly expand therapeutic options, which are currently reserved for lower-grade NEN patients. Moreover, while debated, in our population, primary surgery was performed in 92 and 73.5% of locoregional NET G3 and NEC cases, respectively, indicating that surgery can be considered in locoregional setting. Finally, platinum–etoposide was the predominant first-line treatment in metastatic NEC, with no significant survival difference between carboplatin and cisplatin.
Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients
Irene Assaf, Giacomo Bregni, Geraldine Anthoine, Thomas Aparicio, Pascal Artru, Meher Ben Abdelghani, Marc Buyse, Benoist Chibaudel, Elisabeth Coart, Marie Diaz, Camille Evrard, Karen Geboes, François Ghiringhelli, Francesco Puleo, Judith Raimbourg, Timon Vandamme, Marc Van den Eynde, Alain Hendlisz, Francesco Sclafani
Clinical Colorectal Cancer, 2025
Surgical management of pseudomyxoma peritonei: low-volume center experience
Charif Khaled, Lina Safar, Alain Hendlisz, Maria Gomez Galdon, Paulus Kristanto, Michel Moreau, Ana Veron Sanchez, Gabriel Liberale
Acta Chirurgica Belgica, 2025
INTRODUCTION Pseudomyxoma peritonei (PMP) is a rare disease characterized by diffuse peritoneal invasion of multifocal mucinous deposits. Gold standard treatment involves cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). We aimed to compare the outcomes of operated PMP patients in a low-volume center, with those of high-volume centers and using other regimens. MATERIALS AND METHODS Retrospective analysis was conducted for PMP patients treated by CRS + HIPEC (using the Elias high-dose Oxaliplatin HIPEC regimen) over a 15-year period (January 2007 - December 2021) at the Jules Bordet Institute - H.U.B. RESULTS 32 patients were included. Pathology results were: 21.9% acellular mucin, 34.4% low-grade, and 43.7% high-grade. The median peritoneal cancer index was 24 (range 3-36). The median follow-up was 58 months. The rate of major complications (Clavien-Dindo III/IV) was 41% and postoperative mortality was 3%. Mean disease-free survival (DFS) was estimated at 40 +/- 4 months (standard deviation (SD)) while overall survival (OS) was 122 +/- 9 months (SD). DFS reached a plateau of 44.5% at 5 and 10 years and OS was 92.3% and 76.2% respectively. Statistical analysis showed low-grade PMP to be predictive of better DFS and OS (p = 0.0111 and p = 0.0293 respectively). We also found that female gender was predictive of better DFS (p = 0.0262). CONCLUSION Our postoperative morbidity and mortality rates, DFS, and OS were similar to those reported in the literature for high-volume PMP centers. Our theory is that surgical proficiency can be more attributed to the surgeon's CRS experience, regardless of the nature of the disease.
Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids
Giulia Agostini, Morgane Leprovots, Jérôme Jeandriens, Anne Lefort, Frédérick Libert, Francesco Sclafani, Ingrid Langer, Alain Hendlisz, Marie-Isabelle Garcia
Frontiers in Cell and Developmental Biology, 2025
Colorectal cancer (CRC) remains the second leading cause of cancer-related deaths worldwide, with its incidence continuing to rise. Regorafenib, a multi-kinase inhibitor approved for palliative treatment, has been shown to extend survival in patients with metastatic CRC (mCRC) who have failed standard therapies. However, its clinical benefit is limited to a subset of patients, is typically short-lived, and is often accompanied by significant toxicity. The mechanisms by which CRC cells develop resistance to regorafenib remain incompletely understood. In this study, we investigated the mechanisms of regorafenib resistance using a preclinical mouse colon organoid model. Transcriptomic analysis of Apc wild-type and Apc-deficient organoids treated with regorafenib revealed upregulation of epithelial-to-mesenchymal transition (EMT), alterations in the secretome, and increased activation of phosphorylated Erk1/2. Notably, co-treatment with an autophagy inhibitor suppressed regorafenib-induced EMT and its associated secretory phenotype, leading to reduced cell proliferation and enhanced apoptosis in mouse organoids. The efficacy of this drug combination was further supported by cell viability assays in human CRC cell lines. In contrast, primary mouse colon fibroblasts exhibited greater resistance to both single-agent and combination regorafenib treatments. In summary, our findings using an organoid model suggest that autophagy inhibition may represent a promising strategy to overcome chemoresistance to regorafenib in mCRC patients.
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study
Rachele Danieli, Magdalena Mileva, Gwennaëlle Marin, Paulus Kristanto, Wendy Delbart, Bruno Vanderlinden, Zéna Wimana, Alain Hendlisz, Hugo Levillain, Nick Reynaert, Patrick Flamen, Ioannis Karfis
Ejnmmi Research, 2024
Malignant bowel obstruction: effectiveness and safety of systemic chemotherapy
Rafael Caparica, Larissa Amorim, Paulo Amaral, Lucas Uratani, David Muniz, Alain Hendlisz, Evandro de Azambuja, João Glasberg, Tiago Kenji Takahashi, Elias Abdo Filho, Rodrigo Canellas, Daniel Saragiotto, Jorge Sabbaga, Milena Mak
BMJ Supportive and Palliative Care, 2024
Ectopic ACTH-Dependent Cushing's Syndrome Emerging at a Late Stage of a Mixed Histology Neuroendocrine Neoplasm: A Case Report
Michel Meyers, Ahmad Awada, Ioannis Karfis, Daphné t'Kint de Roodenbeke, Hugo Couvert, Charlotte Hanssens, Alain Hendlisz, Natacha Driessens
Case Reports in Oncology, 2024
177Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors: Data From the Prospective Phase 2 LUMEN Study
Magdalena Mileva, Camille Van Bogaert, Gwennaëlle Marin, Rachele Danieli, Carlos Artigas, Hugo Levillain, Lieveke Ameye, Loubna Taraji-Schiltz, Konstantinos Stathopoulos, Zéna Wimana, Alain Hendlisz, Patrick Flamen, Ioannis Karfis
Clinical Nuclear Medicine, 2024
Beyond 'the good, the bad and the ugly': let us put rectal cancer patients at the centre of the decision making
Francesco Sclafani, Chiara Conti, Chiara Gallio, Alain Hendlisz
Current Opinion in Oncology, 2024
State-of-the-art and trends in fibroblast growth factor receptor-directed therapies in gastro-intestinal malignancies
Charlotte Hanssens, Oumnia Mouna, Michel Meyers, Alain Hendlisz
Current Opinion in Oncology, 2024
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers
Roberta Fazio, Alessandro Audisio, Valentina Daprà, Chiara Conti, Nada Benhima, Fatima-Zahara Abbassi, Irene Assaf, Alain Hendlisz, Francesco Sclafani
Cancer Treatment Reviews, 2024
PD-L1 Expression in Paired Samples of Rectal Cancer
Mina Coussement, Roberta Fazio, Alessandro Audisio, Reem El Khoury, Fatima-Zahra Abbassi, Irene Assaf, Chiara Conti, Chiara Gallio, Nada Benhima, Giacomo Bregni, Paraskevas Gkolfakis, Valentina Spagnolo, Geraldine Anthoine, Gabriel Liberale, Luigi Moretti, Philippe Martinive, Alain Hendlisz, Pieter Demetter, Francesco Sclafani
Cancers, 2024
Current trends of clinical trials for older patients with cancer: A systematic review.
Roberta Fazio, Alessandro Audisio, Everardo D. Saad, Giacomo Bregni, Daniel Genel Sur, Valentina Daprà, Chiara Conti, Fatima-Zahra Abbassi, Nada Benhima, Irene Georges Assaf, Alain Hendlisz, Jean-Luc Van Laethem, Marc E. Buyse, Francesco Sclafani
Journal of Clinical Oncology, 2024
Development of Clinical Radiomics-Based Models to Predict Survival Outcome in Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Study
Ayoub Mokhtari, Roberto Casale, Zohaib Salahuddin, Zelda Paquier, Thomas Guiot, Henry C. Woodruff, Philippe Lambin, Jean-Luc Van Laethem, Alain Hendlisz, Maria Antonietta Bali
Diagnostics, 2024
Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
Magdalena Mileva, Gwennaëlle Marin, Hugo Levillain, Carlos Artigas, Camille Van Bogaert, Clémentine Marin, Rachele Danieli, Amelie Deleporte, Simona Picchia, Konstantinos Stathopoulos, Christiane Jungels, Bruno Vanderlinden, Marianne Paesmans, Lieveke Ameye, Gabriela Critchi, Loubna Taraji-Schiltz, Chloe Velghe, Zéna Wimana, Maria Bali, Alain Hendlisz, Patrick Flamen, Ioannis Karfis
Journal of Nuclear Medicine, 2024
Neoadjuvant chemotherapy for early-stage colon cancer
Alessandro Audisio, Roberta Fazio, Valentina Daprà, Irene Assaf, Alain Hendlisz, Francesco Sclafani
Cancer Treatment Reviews, 2024
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with micro-satellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142
Heinz-Josef Lenz, Michael J. Overman, Eric Van Cutsem, Maria Luisa Limon, Ka Yeung Mark Wong, Alain Hendlisz, Massimo Aglietta, Pilar Garcia-Alfonso, Bart Neyns, Fabio Gelsomino, Dana Backlund Cardin, Tomislav Dragovich, Usman Shah, Stephen McCraith, Rui Wang, Ming Lei, Jin Yao, Lixian Jin, Sara Lonardi
Journal of Clinical Oncology, 2024
Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer
Irene Assaf, Danai Fimereli, Geraldine Anthoine, Roberta Fazio, Valentina Daprà, Alessandro Audisio, Alina Bardiaux, Tugba Akin Telli, Michele Vanhooren, Rita Saude-Conde, Giacomo Bregni, Alain Hendlisz, Francesco Sclafani
Cancers, 2023
Association between primary tumor characteristics and histopathological growth pattern of liver metastases in colorectal cancer
Ali Bohlok, Camille Tonneau, Sophie Vankerckhove, Ligia Craciun, Valerio Lucidi, Fikri Bouazza, Alain Hendlisz, Jean Luc Van Laethem, Denis Larsimont, Peter Vermeulen, Vincent Donckier, Pieter Demetter
Clinical and Experimental Metastasis, 2023
Immunotherapies in non-metastatic gastrointestinal cancers
Rita Saúde-Conde, Dan Nguyen, Alain Hendlisz
Current Opinion in Oncology, 2023
Neoadjuvant chemotherapy for resectable colon cancer in the era of precision oncology: a step forward or a step back?
Alessandro Audisio, Roberta Fazio, Alain Hendlisz, Francesco Sclafani
Current Opinion in Oncology, 2023
Editorial introductions
Jean‐Yves Blay, Hindi, Nadia, Alain Hendlisz, Francesco Sclafani
Current Opinion in Oncology, 2023
The Prognostic Value of Distinct Histological Growth Patterns of Colorectal Peritoneal Metastases: A Pilot Study
Antoine El Asmar, Pieter Demetter, Fahd Fares, Francesco Sclafani, Alain Hendlisz, Vincent Donckier, Peter Vermeulen, Gabriel Liberale
Annals of Surgical Oncology, 2023
Preexisting evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review
Giacomo Bregni, Elena Trevisi, Rita Saúde Conde, Michele Vanhooren, Tugba Akin Telli, Irene Assaf, Alain Hendlisz, Massimo Di Maio, Francesco Sclafani
Journal of the National Cancer Institute, 2023
Tumor biology reflected by histological growth pattern is more important than surgical margin for the prognosis of patients undergoing resection of colorectal liver metastases
Ali Bohlok, Lisa Inchiostro, Valerio Lucidi, Sophie Vankerckhove, Alain Hendlisz, Jean Luc Van Laethem, Ligia Craciun, Pieter Demetter, Denis Larsimont, Luc Dirix, Peter Vermeulen, Vincent Donckier
European Journal of Surgical Oncology, 2023
Histopathological growth pattern of liver metastases as an independent marker of metastatic behavior in different primary cancers
Ali Bohlok, François Richard, Valerio Lucidi, Antoine El Asmar, Pieter Demetter, Ligia Craciun, Denis Larsimont, Alain Hendlisz, Jean Luc Van Laethem, Luc Dirix, Christine Desmedt, Peter Vermeulen, Vincent Donckier
Frontiers in Oncology, 2023
Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer
Tugba Akin Telli, Giacomo Bregni, Michele Vanhooren, Rita Saude Conde, Alain Hendlisz, Francesco Sclafani
Cancer Treatment Reviews, 2022
Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance
Pashalina Kehagias, Nadège Kindt, Mohammad Krayem, Ahmad Najem, Giulia Agostini, Elena Acedo Reina, Giacomo Bregni, Francesco Sclafani, Fabrice Journe, Ahmad Awada, Ghanem E. Ghanem, Alain Hendlisz
Cells, 2022
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
T. André, S. Lonardi, K.Y.M. Wong, H.-J. Lenz, F. Gelsomino, M. Aglietta, M.A. Morse, E. Van Cutsem, R. McDermott, A. Hill, M.B. Sawyer, A. Hendlisz, B. Neyns, S. Abdullaev, A. Memaj, M. Lei, M. Dixon, S. Kopetz, M.J. Overman
Annals of Oncology, 2022
Editorial: 'All you need is immunotherapy': A new treatment paradigm in sight for early-stage, mismatch repair-deficient/microsatellite instability high gastrointestinal cancers?
Francesco Sclafani, Alain Hendlisz
Current Opinion in Oncology, 2022
Mind the target: Human epidermal growth factor receptor 2 in colorectal cancer
Rita Saúde-Conde, Gertjan Rasschaert, Giacomo Bregni, Alain Hendlisz, Francesco Sclafani
Current Opinion in Oncology, 2022
Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer
Erwin Woff, Lisa Salvatore, Federica Marmorino, Dario Genovesi, Gabriela Critchi, Thomas Guiot, Lieveke Ameye, Francesco Sclafani, Alain Hendlisz, Patrick Flamen
Journal of Nuclear Medicine, 2022
JCOG0603: Are We Really Sure This Was a Negative Trial?
Rita Saude Conde, Giacomo Bregni, Everardo Saad, Alain Hendlisz, Francesco Sclafani
Journal of Clinical Oncology, 2022
Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy
P.J. Ross, H.S. Wasan, D. Croagh, M. Nikfarjam, N. Nguyen, M. Aghmesheh, A.M. Nagrial, D. Bartholomeusz, A. Hendlisz, T. Ajithkumar, C. Iwuji, N.E. Wilson, D.M. Turner, D.C. James, E. Young, M.T. Harris
ESMO Open, 2022
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/ Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
Heinz-Josef Lenz, Eric Van Cutsem, Maria Luisa Limon, Ka Yeung Mark Wong, Alain Hendlisz, Massimo Aglietta, Pilar García-Alfonso, Bart Neyns, Gabriele Luppi, Dana B. Cardin, Tomislav Dragovich, Usman Shah, Sandzhar Abdullaev, Joseph Gricar, Jean-Marie Ledeine, Michael James Overman, Sara Lonardi
Journal of Clinical Oncology, 2022
Circulating DNA in the neoadjuvant setting of early stage colon cancer
Giacomo Bregni, Andrea Pretta, Chiara Senti, Elena Acedo Reina, Caroline Vandeputte, Elena Trevisi, Paraskevas Gkolfakis, Pashalina Kehagias, Amélie Deleporte, Jean-Luc Van Laethem, Philippe Vergauwe, Marc Van den Eynde, Guido Deboever, Jos Janssens, Gauthier Demolin, Stephane Holbrechts, Marylene Clausse, Thierry De Grez, Marc Peeters, Lionel D'Hondt, Karen Geboes, Tatiana Besse-Hammer, Françoise Rothé, Patrick Flamen, Alain Hendlisz, Francesco Sclafani
Acta Oncologica, 2022
Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial
Caroline Vandeputte, Giacomo Bregni, Paraskevas Gkolfakis, Thomas Guiot, Andrea Pretta, Pashalina Kehagias, Chiara Senti, Elena Acedo Reina, Camille Van Bogaert, Amélie Deleporte, Karen Geboes, Thierry Delaunoit, Gauthier Demolin, Marc Peeters, Lionel D'Hondt, Jos Janssens, Javier Carrasco, Stephane Holbrechts, Jean-Charles Goeminne, Philippe Vergauwe, Jean-Luc Van Laethem, Patrick Flamen, Alain Hendlisz, Francesco Sclafani
Clinical Colorectal Cancer, 2021
Targeted agents in older patients with gastrointestinal cancers – An overview
Ana Raquel Monteiro, Rita Saúde Conde, Raquel Basto, Francesco Sclafani, Amélie Deleporte, Alain Hendlisz, Lissandra Dal Lago
Journal of Geriatric Oncology, 2021
Editorial: Radioembolization for metastatic colorectal cancer: Towards maturity, at last?
Alain Hendlisz, Francesco Sclafani
Current Opinion in Oncology, 2021
Anal squamous cell carcinoma: Standards of care, new data and ongoing clinical trials
Emilio Francesco Giunta, Giacomo Bregni, Alain Hendlisz, Francesco Sclafani
Current Opinion in Oncology, 2021
Editorial introductions
Current Opinion in Oncology, 2021
The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis
Deborah J. Repullo, Sandrine Barbois, Daniel Leonard, Ali Bohlok, Estelle T. Van den Audenaeren, Alain Hendlisz, Marc Van den Eynde, Vincent Donckier, Alex Kartheuser, Gabriel Liberale
European Journal of Surgical Oncology, 2021
Fortnightly or fractionated weekly docetaxel–cisplatin–5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study
Amélie Deleporte, Marc Van den Eynde, Frédéric Forget, Stéphane Holbrechts, Thierry Delaunoit, Ghislain Houbiers, Hassan R. Kalantari, Stéphanie Laurent, Erik Vanderstraeten, Marc De Man, Philippe Vergauwe, Marylene Clausse, Jacques Van Der Auwera, Lionel D’Hondt, Pascal Pierre, Bjorn Ghillemijn, Angelique Covas, Marianne Paesmans, Lieveke Ameye, Ahmad Awada, Francesco Sclafani, Alain Hendlisz
Cancer Medicine, 2021
The histological growth pattern and the clinico-metabolic characteristics accurately predict the outcome in patients undergoing surgery for colorectal liver metastases - Belgian Group for Digestive Oncology (BGDO)
Ali BOHLOK, Ivan DURAN DERIJCKERE, Hugues AZEMA, Valerio LUCIDI, Sophie VANKERCKHOVE, Alain HENDLISZ, Jean Luc VAN LAETHEM, Serge GOLDMAN, Patrick FLAMEN, Denis LARSIMONT, Pieter DEMETTER, Luc DIRIX, Peter VERMEULEN, Vincent DONCKIER
Annals of Hepato Biliary Pancreatic Surgery, 2021
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials
E.F. Giunta, G. Bregni, A. Pretta, A. Deleporte, G. Liberale, A.M. Bali, L. Moretti, T. Troiani, F. Ciardiello, A. Hendlisz, F. Sclafani
Cancer Treatment Reviews, 2021
Clinico-metabolic characterization improves the prognostic value of histological growth patterns in patients undergoing surgery for colorectal liver metastases
Ali Bohlok, Ivan Duran Derijckere, Hugues Azema, Valerio Lucidi, Sophie Vankerckhove, Alain Hendlisz, Jean Luc Van Laethem, Irina Vierasu, Serge Goldman, Patrick Flamen, Denis Larsimont, Pieter Demetter, Luc Dirix, Peter Vermeulen, Vincent Donckier
Journal of Surgical Oncology, 2021
Buschke-löwenstein tumor in a human immunodeficiency virus-positive patient: A case report and short literature review
V Ledouble, F Sclafani, A Hendlisz, M Gomez Galdon, G Liberale
Acta Gastro Enterologica Belgica, 2021
Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma
Christelle Bouchart, Jean-Luc Engelholm, Jean Closset, Julie Navez, Patrizia Loi, Yeter Gökburun, Thierry De Grez, Laura Mans, Alain Hendlisz, Maria Antonietta Bali, Pierre Eisendrath, Dirk Van Gestel, Matthieu Hein, Luigi Moretti, Jean-Luc Van Laethem
Therapeutic Advances in Medical Oncology, 2021
Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer
Giacomo Bregni, Caroline Vandeputte, Andrea Pretta, Chiara Senti, Elena Trevisi, Elena Acedo Reina, Pashalina Kehagias, Gabriel Liberale, Luigi Moretti, Maria Antonietta Bali, Pieter Demetter, Patrick Flamen, Javier Carrasco, Lionel D'Hondt, Karen Geboes, Yeter Gokburun, Marc Peeters, Marc Van den Eynde, Jean-Luc Van Laethem, Philippe Vergauwe, Camille Anastasia Chapot, Marc Buyse, Amelie Deleporte, Alain Hendlisz, Francesco Sclafani
Acta Oncologica, 2021
Postoperative C-reactive protein kinetics predict postoperative complications in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis
Antoine El Asmar, Melissa Bendavides, Michel Moreau, Alain Hendlisz, Amélie Deleporte, Maher Khalife, Vincent Donckier, Gabriel Liberale
World Journal of Surgical Oncology, 2020
MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer
Silvia Camera, Amélie Deleporte, Giacomo Bregni, Elena Trevisi, Andrea Pretta, Tugba Akin Telli, Laura Polastro, Andrea Gombos, Aline Kayumba, Lieveke Ameye, Martine Piccart-Gebhart, Ahmad Awada, Francesco Sclafani, Alain Hendlisz
Clinical Colorectal Cancer, 2020
Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients
Ali Bohlok, Peter Vermeulen, Sophia Leduc, Emily Latacz, Lara Botzenhart, François Richard, Maxim De Schepper, Tatjana Geukens, Valerio Lucidi, Michail Ignatiadis, Philippe Aftimos, Christos Sotiriou, Martine Piccart, Alain Hendlisz, Steven Van Laere, Luc Dirix, Jean-Christophe Noël, Elia Biganzoli, Denis Larsimont, Christine Desmedt, Vincent Donckier
Npj Breast Cancer, 2020
Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel
Giacomo Bregni, Tiberio Sticca, Silvia Camera, Tugba Akin Telli, Ligia Craciun, Elena Trevisi, Andrea Pretta, Pashalina Kehagias, Sophia Leduc, Chiara Senti, Amélie Deleporte, Caroline Vandeputte, Everardo Delforge Saad, Joseph Kerger, Thierry Gil, Martine Piccart-Gebhart, Ahmad Awada, Pieter Demetter, Denis Larsimont, Alain Hendlisz, Philippe Aftimos, Francesco Sclafani
Acta Oncologica, 2020
Treatment compliance in early-stage anal cancer
A. Pretta, E. Trevisi, G. Bregni, A. Deleporte, A. Hendlisz, F. Sclafani
Annals of Oncology, 2020
Fat density is a novel prognostic marker in patients with esophageal cancer
Maëlle Anciaux, André Van Gossum, Cynthia Wenglinski, Lieveke Ameye, Thomas Guiot, Patrick Flamen, Pieter Demetter, Amélie Deleporte, Francesco Sclafani, Vincent Donckier, Alain Hendlisz, Caroline Vandeputte
Clinical Nutrition Espen, 2020
Prognostic value of the pace of tumor progression as assessed by serial18 f-fdg pet/ct scan and liquid biopsy in refractory colorectal cancer: The coriolan trial
Silvia Camera, Tugba Akin Telli, Erwin Woff, Caroline Vandeputte, Pashalina Kehagias, Thomas Guiot, Gabriela Critchi, Yacine Wissam, Giacomo Bregni, Elena Trevisi, Andrea Pretta, Chiara Senti, Sophia Leduc, Paraskevas Gkolfakis, Frédéric Hoerner, Françoise Rothé, Francesco Sclafani, Patrick Flamen, Amelie Deleporte, Alain Hendlisz
Cancers, 2020
Current practice in approaching controversial diagnostic and therapeutic topics in gastroenteropancreatic neuroendocrine neoplasm management. Belgian multidisciplinary expert discussion based on a modified delphi method
Acta Gastro Enterologica Belgica, 2020
Infiltrative tumour growth pattern correlates with poor outcome in oesophageal cancer
Maelle Anciaux, Pieter Demetter, Roland De Wind, Maria Gomez Galdon, Sylvie Vande Velde, Gaspard Lens, Ligia Craciun, Amélie Deleruelle, Denis Larsimont, Tom Lenaerts, Francesco Sclafani, Amélie Deleporte, Vincent Donckier, Alain Hendlisz, Caroline Vandeputte
BMJ Open Gastroenterology, 2020
Editorial: Adjuvant chemotherapy for gastrointestinal cancers: we can do much better
Francesco Sclafani, Alain Hendlisz
Current Opinion in Oncology, 2020
Imaging and clinical correlates with regorafenib in metastatic colorectal cancer
Khurum Khan, Stefano Cascinu, David Cunningham, Sun-Young Kim, Eiji Oki, Tara Seery, Lin Shen, Salvatore Siena, Christophe Tournigand, Nazim Serdar Turhal, Alain Hendlisz
Cancer Treatment Reviews, 2020
The lack of selection criteria for surgery in patients with non-colorectal non-neuroendocrine liver metastases
Ali Bohlok, Valerio Lucidi, Fikri Bouazza, Ali Daher, Desislava Germanova, Jean Luc Van Laethem, Alain Hendlisz, Vincent Donckier
World Journal of Surgical Oncology, 2020
Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials
Rafael Caparica, Marco Bruzzone, Georges El Hachem, Marcello Ceppi, Matteo Lambertini, João Glasberg, Evandro de Azambuja, Jean-Luc Van Laethem, Alain Hendlisz
Critical Reviews in Oncology Hematology, 2020
Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors
Maria Alice Franzoi, Caroline Vandeputte, Daniel Eiger, Rafael Caparica, Mariana Brandão, Claudia De Angelis, Alain Hendlisz, Ahmad Awada, Martine Piccart, Evandro de Azambuja
Breast Cancer Research and Treatment, 2020
Personalized selective internal radiation therapy in liver metastasis of thyroid cancer with impaired liver function: A case report
Maxime Herchuelz, Gwennaëlle Marin, Ivan Duran Derijckere, Michaël Vouche, Philippe Delatte, Vincent Donckier, Gabriel Liberale, Alain Hendlisz, Carlos Artigas, Pierre Bourgeois, Patrick Flamen
Radiology Case Reports, 2020
Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: A rationale for combining selective internal radiation therapy (SIRT) and immunotherapy
Ligia Craciun, Roland de Wind, Pieter Demetter, Valerio Lucidi, Ali Bohlok, Sébastien Michiels, Fikri Bouazza, Michael Vouche, Ilario Tancredi, Gontran Verset, Soizic Garaud, Céline Naveaux, Maria Gomez Galdon, Karen Willard Gallo, Alain Hendlisz, Ivan Duran Derijckere, Patrick Flamen, Denis Larsimont, Vincent Donckier
BMC Cancer, 2020
Prognostic value of a three-scale grading system based on combining molecular imaging with 68Ga-DOTATATE and 18F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias
Oncotarget, 2020
Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice
G. Bregni, T. Akin Telli, S. Camera, A. Deleporte, L. Moretti, A.M. Bali, G. Liberale, S. Holbrechts, A. Hendlisz, F. Sclafani
Cancer Treatment Reviews, 2020
The metabolic clinical risk score as a new prognostic model for surgical decision-making in patients with colorectal liver metastases
Ivan Duran Derijckere, Hugo Levillain, Ali Bohlok, Celine Mathey, Jonathan Nezri, Raoul Muteganya, Nicola Trotta, Valerio Lucidi, Fikri Bouazza, Desislava Germanova, Gaetan Van Simaeys, Serge Goldman, Alain Hendlisz, Patrick Flamen, Vincent Donckier
Journal of Surgical Oncology, 2020
PD-1 and PD-L1 inhibitors in oesophago-gastric cancers
Tugba Akin Telli, Giacomo Bregni, Silvia Camera, Amelie Deleporte, Alain Hendlisz, Francesco Sclafani
Cancer Letters, 2020
Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?
Christelle Bouchart, Julie Navez, Jean Closset, Alain Hendlisz, Dirk Van Gestel, Luigi Moretti, Jean-Luc Van Laethem
Therapeutic Advances in Medical Oncology, 2020
Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelines
G. Bregni, T. Akin Telli, S. Camera, C. Baratelli, L. Shaza, A. Deleporte, L. Moretti, M.A. Bali, G. Liberale, A. Hendlisz, F. Sclafani
Cancer Treatment Reviews, 2020
Combining 18F-FDG PET/CT-based metabolically active tumor volume and circulating cell-free DNA significantly improves outcome prediction in chemorefractory metastatic colorectal cancer
Erwin Woff, Pashalina Kehagias, Caroline Vandeputte, Lieveke Ameye, Thomas Guiot, Marianne Paesmans, Alain Hendlisz, Patrick Flamen
Journal of Nuclear Medicine, 2019
Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study
Hugo Levillain, Ivan Duran Derijckere, Lieveke Ameye, Thomas Guiot, Arthur Braat, Carsten Meyer, Bruno Vanderlinden, Nick Reynaert, Alain Hendlisz, Marnix Lam, Christophe M. Deroose, Hojjat Ahmadzadehfar, Patrick Flamen
European Journal of Nuclear Medicine and Molecular Imaging, 2019
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
Lorraine Springuel, Caroline Lonez, Bertrand Alexandre, Eric Van Cutsem, Jean-Pascal H. Machiels, Marc Van Den Eynde, Hans Prenen, Alain Hendlisz, Leila Shaza, Javier Carrasco, Jean-Luc Canon, Mateusz Opyrchal, Kunle Odunsi, Sylvie Rottey, David E. Gilham, Anne Flament, Frédéric F. Lehmann
Biodrugs, 2019
PRODIGE 7 should be interpreted with caution
Gabriel Liberale, Lieveke Ameye, Alain Hendlisz
Acta Chirurgica Belgica, 2019
Adjuvant chemotherapy for rectal cancer: playing the devil’s advocate
Francesco Sclafani, Alain Hendlisz
Current Opinion in Oncology, 2019
Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma
Corentin Delhaye, Alain Hendlisz, Michael Vouche
Current Opinion in Oncology, 2019
CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: A companion study to the PePiTA trial
Françoise Rothé, Marion Maetens, Ghizlane Rouas, Marianne Paesmans, Marc Van den Eynde, Jean-Luc Van Laethem, Philippe Vergauwe, Guido Deboever, Yacine Bareche, Caroline Vandeputte, Michail Ignatiadis, Alain Hendlisz
BMC Cancer, 2019
Folfiri as second-line treatment of metastatic biliary tract cancer patients
Rafael Caparica, Adrien Lengelé, Winnie Bekolo, Alain Hendlisz
Autopsy and Case Reports, 2019
Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: A post hoc analysis of two non-randomized phase II trials
Nicolas Charette, Caroline Vandeputte, Lieveke Ameye, Camille Van Bogaert, Jonathan Krygier, Thomas Guiot, Amélie Deleporte, Thierry Delaunoit, Karen Geboes, Jean-Luc Van Laethem, Marc Peeters, Gauthier Demolin, Stéphane Holbrechts, Patrick Flamen, Marianne Paesmans, Alain Hendlisz
BMC Cancer, 2019
Validation of metabolically active tumor volume and total lesion glycolysis as 18 F-FDG PET/CT–derived prognostic biomarkers in chemorefractory metastatic colorectal cancer
Erwin Woff, Alain Hendlisz, Lieveke Ameye, Camilo Garcia, Tarek Kamoun, Thomas Guiot, Marianne Paesmans, Patrick Flamen
Journal of Nuclear Medicine, 2019
Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies
Peter Gibbs, Volker Heinemann, Navesh K. Sharma, Julien Taieb, Jens Ricke, Marc Peeters, Michael Findlay, Bridget Robinson, Christopher Jackson, Andrew Strickland, Val Gebski, Mark Van Buskirk, Huaqing Zhao, Guy van Hazel, Michael Brown, Matthew Burge, Giuseppe Cardaci, Stephen Clarke, Paul Eliadis, Tom Ferguson, Vinod Ganju, Peter Gibbs, Guy van Hazel, Philip James, Chris Karapetis, Winston Liauw, Gavin Marx, Marco Matos, Louise Nott, Nick Pavlakis, Alex Powell, Timothy Price, David Ransom, Eva Segelov, Jenny Shannon, Nimit Singhal, Andrew Strickland, Euan Walpole, Michel Craninx, Thierry Delaunoit, Amélie Deleporte, Michel Ferrante, Karen Geboes, Alain Hendlisz, Koen Hendrickx, Marc De Man, Els Monsaert, Veerle Moons, Marc Peeters, Marc Polus, Eveline Boucher, Jacques Balosso, Patrick Chevallier, Samy Louafi, Marc Pracht, Christine Rebischung, Denis Smith, Julien Taieb, Eric Terrebonne, Harald-Robert Bruch, Gerald Gehbauer, Volker Heinemann, Thomas Helmberger, Yon-Dschun Ko, Hendrik Kröning, Frank Lammert, Arnd Nusch, Stefan Pluntke, Karsten Ridwelski, Jorge Riera-Knorrenschild, Hanno Riess, Jorge Ramon Riera, Jens Ricke, Tilmann Sauerbruch, Klemens Scheidhauer, Oliver Stötzer, Klaus Tatsch, Ursula Vehling-Kaiser, Thomas Vogl, Alex Beny, Ravit Geva, Einat Shacham-Shmueli, Salomon Stemmer, Thomas Tichler, Ido Wolf, Bruna Angelelli, Andrea Martoni, Michael P.N. Findlay, Richard Isaacs, Anne O’Donnell, David Perez, Bridget A. Robinson, Javier Rodríguez, Ruth Vera-Garcia, Pradip Amin, Daniel Bloomgarden, James Bui, James Carlisle, Seungjean Chai, Yi-Jen Chen, Michael Chuong, Andrew Coveler, Francis Facchini, Gary Frenette, Jacob Frick, Michael Garofalo, Benjamin George, Michael Gordon, Seza Gulec, James Hannigan, Matthew Holtzman, Andreas Kaubisch, Adeel Kaiser, Todd Kooy, Steven Limentani, Jeffrey Margolis, Robert Martin, Howard Ozer, Siddarth Padia, William Rilling, Michael Savin, Elyse Schneiderman, Grant Seeger, Navesh Sharma, Stephen Shibata, Randall Smith, Eric Wang, Samuel Whiting, Morteza Aghmesheh, Mathew Burge, Prasad Cooray, Kynan Feeney, Tom Ferguson, Vinod Ganju, Peter Gibbs, Guy van Hazel, Lionel Lim, Marco Matos, Louise Nott, Madhu Singh, Nimit Singhal, Andrew Strickland, Craig Underhill, Euan Walpole, Amelie Deleporte, Alain Hendlisz, Koen Hendrickx, Marc De Man, Els Monsaert, Marc Peeters, Marc Polus, Eveline Boucher, Aurelie Durand, Sandrine Faivre, Aurelie Ferru, Pascal Hammel, Samy Louafi, Marc Pracht, Christine Rebischung, Denis Smith, Julien Taieb, Eric Terrebonne, Christoph Bremer, Maike De Wit, Hendrik Kröning, Hubert Ayala, Alex Beny, Ravit Geva, Norman Heching, Adi Shani, Thomas Tichler, Bruna Angelelli, Cristina Granetto, Gianluca Masi, Stefania Mosconi, Gianmauro Numico, Antonio Trogu, Yeul Hong Kim, Han Sae-Won, Michael P.N. Findlay, Richard Isaacs, Chris Jackson, Anne O'Donnell, Maria Fragoso, Iain Tan, Ana Ruiz Casado, Ruth Vera-Garcia, Jin Tung Liang, Jin Hwang Liu, Steven Ades, Miklos Auber, Daniel Bloomgarden, Patrick Boland, Charles Bowers, James Bui, James Carlisle, Seungjean Chai, Michael Chuong, Martin Crain, Kyran Dowling, Francis Facchini, Gary Frenette, Jacob Frick, Matthew Holtzman, Renuka Iyer, Adeel Kaiser, Andreas Kaubisch, Steven Limentani, Lynn Ratner, Federico Sanchez, Navesh Sharma, Patricia Stoltzfus, Eric Wang, Mark Westcott
Clinical Colorectal Cancer, 2018
The potential benefit of adjuvant chemotherapy in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy is not predicted by tumor regression grade
Ali Bohlok, Alain Hendlisz, Fikri Bouazza, Maria Gomez Galdon, Jean Van de Stadt, Luigi Moretti, Issam El Nakadi, Gabriel Liberale
International Journal of Colorectal Disease, 2018
The unbearable lightness of therapeutic algorithms in colorectal liver metastasis
Alain Hendlisz, Vincent Donckier
Current Opinion in Oncology, 2018
Pseudoadjuvant chemotherapy in resectable metastatic colorectal cancer
Laura Polastro, Georges El Hachem, Alain Hendlisz
Current Opinion in Oncology, 2018
Acute Pancreatitis Following Peptide Receptor Radionuclide Therapy: An Unusual Adverse Event
Ioannis Karfis, Gwennaëlle Marin, Godelieve Machiels, Alain Hendlisz, Patrick Flamen
Clinical Nuclear Medicine, 2018
The concept of oligometastases in colorectal cancer: From the clinical evidences to new therapeutic strategies
Edouard Massaut, Ali Bohlok, Valerio Lucidi, Alain Hendlisz, Jean A. Klastersky, Vincent Donckier
Current Opinion in Oncology, 2018
Selective internal radiation therapy (SIRT) before partial hepatectomy or radiofrequency destruction for treatment of hepatocellular carcinoma in cirrhotic patients: a feasibility and safety pilot study
Mégane Lemaire, Valerio Lucidi, Fikri Bouazza, Georgios Katsanos, Bruno Vanderlinden, Hugo Levillain, Philippe Delatte, Camilo A. Garcia, Michael Vouche, Maria Gomez Galdon, Pieter Demetter, Amélie Deleporte, Alain Hendlisz, Patrick Flamen, Vincent Donckier
HPB, 2018
Celyad's novel CAR T-cell therapy for solid malignancies
Caroline Lonez, Alain Hendlisz, Leila Shaza, Philippe Aftimos, Michaël Vouche, Vincent Donckier, Jean-Pascal H. Machiels, Marc Van Den Eynde, Jean-Luc Canon, Javier Carrasco, Kunle Odunsi, Solmaz Sahebjam, Sylvie Rottey, Nathalie Braun, Bikash Verma, David E. Gilham, Frédéric F. Lehmann
Current Research in Translational Medicine, 2018
Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multikinase inhibitor
Caroline Vandeputte, Pashalina Kehagias, Hakim El Housni, Lieveke Ameye, Jean-François Laes, Christine Desmedt, Christos Sotiriou, Amélie Deleporte, Francesco Puleo, Karen Geboes, Thierry Delaunoit, Gauthier Demolin, Marc Peeters, Lionel D’Hondt, Jos Janssens, Javier Carrasco, Raphaël Marechal, Maria Gomez Galdon, Pierre Heimann, Marianne Paesmans, Patrick Flamen, Alain Hendlisz
Oncotarget, 2018
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong, Heinz-Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Magali Svrcek, Rebecca A. Moss, Jean-Marie Ledeine, Z. Alexander Cao, Shital Kamble, Scott Kopetz, Thierry André
Journal of Clinical Oncology, 2018
90Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer
Hugo Levillain, Ivan Duran Derijckere, Gwennaëlle Marin, Thomas Guiot, Michaël Vouche, Nick Reynaert, Alain Hendlisz, Bruno Vanderlinden, Patrick Flamen
Ejnmmi Research, 2018
Sequential tumor-directed and lobar radioembolization before major hepatectomy for hepatocellular carcinoma
Michael Vouche, Thierry Degrez, Fikri Bouazza, Philippe Delatte, Maria Gomez Galdon, Alain Hendlisz, Patrick Flamen, Vincent Donckier
World Journal of Hepatology, 2017
Study protocol for THINK: A multinational open-label phase i study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types
Caroline Lonez, Bikash Verma, Alain Hendlisz, Philippe Aftimos, Ahmad Awada, Eric Van Den Neste, Gaetan Catala, Jean-Pascal H Machiels, Fanny Piette, Jason B Brayer, David A Sallman, Tessa Kerre, Kunle Odunsi, Marco L Davila, David E Gilham, Frédéric F Lehmann
BMJ Open, 2017
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
Harpreet S Wasan, Peter Gibbs, Navesh K Sharma, Julien Taieb, Volker Heinemann, Jens Ricke, Marc Peeters, Michael Findlay, Andrew Weaver, Jamie Mills, Charles Wilson, Richard Adams, Anne Francis, Joanna Moschandreas, Pradeep S Virdee, Peter Dutton, Sharon Love, Val Gebski, Alastair Gray, Richard Adams, Andrew Bateman, Claire Blesing, Ewan Brown, Ian Chau, Sebastian Cummins, David Cunningham, Stephen Falk, Maher Hadaki, Marcia Hall, Tamas Hickish, Joanne Hornbuckle, Fiona Lofts, Sarah Lowndes, Astrid Mayer, Matthew Metcalfe, Gary Middleton, Jamie Mills, Amir Montazeri, Rebecca Muirhead, Andreas Polychronis, Colin Purcell, Paul Ross, Ricky A Sharma, Liz Sherwin, David Smith, Rubin Soomal, Daniel Swinson, Axel Walther, Harpreet Wasan, Andrew Weaver, Charles Wilson, Greg Wilson, Pradip Amin, Bruna Angelelli, Jacques Balosso, Alex Beny, Daniel Bloomgarden, Evelyn Boucher, Michael Brown, Harald-Robert Bruch, James Bui, Matthew Burge, Giuseppe Cardaci, James Carlisle, Seungjean Chai, Yi-Jen Chen, Patrick Chevallier, Michael Chuong, Stephen Clarke, Andrew Coveler, Michael Craninx, Thierry Delanoit, Amélie Deleporte, Paul Eliadis, Francis Facchini, Thomas Ferguson, Michel Ferrante, Michael Findlay, Gary Frenette, Jacob Frick, Vinod Ganju, Michael Garofalo, Karen Geboes, Gerald Gehbauer, Benjamin George, Ravit Geva, Peter Gibbs, Michael Gordon, Kate Gregory, Seza Gulec, James Hannigan, Guy van Hazel, Norman Heching, Volker Heinemann, Thomas Helmberger, Alain Hendlisz, Koen Hendrickx, Matthew Holtzman, Richard Isaacs, Christopher Jackson, Philip James, Adeel Kaiser, Chris Karapetis, Andreas Kaubisch, Yon-Dschun Ko, Hendrik Kröning, Frank Lammert, Winston Liauw, Steven Limentani, Samy Louafi, Marc de Man, Jeffrey Margolis, Robert Martin, Andrea Martoni, Gavin Marx, Marco Matos, Els Monsaert, Veerle Moons, Louise Nott, Arnd Nusch, Anne O'Donnell, Howard Ozer, Siddarth Padia, Nick Pavlakis, Marc Peeters, David Perez, Stefan Pluntke, Marc Polus, Alex Powell, Marc Pracht, Timothy Price, David Ransom, Christine Rebischung, Jens Ricke, Karsten Ridwelski, Jorge Riera-Knorrenschild, Hanno Riess, William Rilling, Bridget Robinson, Javier Rodríguez, Federico Sanchez, Tilmann Sauerbruch, Michael Savin, Klemens Scheidhauer, Elyse Schneiderman, Grant Seeger, Eva Segelov, Einat Shaham Schmueli, Adi Shani, Jenny Shannon, Navesh Sharma, Stephen Shibata, Nimit Singhal, Denis Smith, Randall Smith, Salomon Stemmer, Oliver Stötzer, Andrew Strickland, Julien Taieb, Klaus Tatsch, Eric Terrebonne, Thomas Tichler, Ursula Vehling-Kaiser, Ruth Vera-Garcia, Thomas Vogl, Euan Walpole, Eric Wang, Samuel Whiting, Ido Wolf, Steven Ades, Morteza Aghmesheh, Bruna Angelelli, Miklos Auber, Hubert Ayala, Alex Beny, Daniel Bloomgarden, Patrick Boland, Eveline Bouche, Charles Bowers, Christoph Bremer, James Bui, Mathew Burge, James Carlisle, Ana Ruiz Casado, Seungjean Chai, Michael Chuong, Prasad Cooray, Martin Crain, Maike De Wit, Kyran Dowling, Aurelie Durand, Francis Facchini, Sandrine Faivre, Kynan Feeney, Tom Ferguson, Aurelie Ferru, Michael Findlay, Maria Fragoso, Gary Frenette, Jacob Frick, Vinod Ganju, Ravit Geva, Peter Gibbs, Cristina Granetto, Pascal Hammel, Guy van Hazel, Norman Heching, Alain Hendlisz, Koen Hendrickx, Matthew Holtzman, Richard Issacs, Renuka Iyer, Christopher Jackson, Adeel Kaiser, Andreas Kaubisch, Yeul Hong Kim, Hendrik Kröning, Jin Tung Liang, Lionel Lim, Steven Limentani, Jin Hwang Liu, Samy Louafi, Marc de Man, Gianluca Masi, Marco Matos, Els Monsaert, Stefania Mosconi, Louise Nott, Gianmauro Numico, Anne O'Donnell, Marc Peeters, Marc Polus, Marc Pracht, Lynn Ratner, Christine Rebischung, Han Sae-Won, Federico Sanchez, Adi Shani, Navesh Sharma, Madhu Singh, Nimit Singhal, Denis Smith, Patricia Stoltzfus, Andrew Strickland, Julien Taieb, Iain Tan, Eric Terrebonne, Thomas Tichler, Antonio Trogu, Craig Underhill, Ruth Vera-Garcia, Euan Walpole, Eric Wang, Mark Westcott, Guy van Hazel, Ricky A Sharma
Lancet Oncology, 2017
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
Jean-François Emile, Catherine Julié, Karine Le Malicot, Come Lepage, Josep Tabernero, Enrico Mini, Gunnar Folprecht, Jean-Luc Van Laethem, Stéphanie Dimet, Camille Boulagnon-Rombi, Marc-Antoine Allard, Frédérique Penault-Llorca, Jaafar Bennouna, Pierre Laurent-Puig, Julien Taieb, Josef Thaler, Richard Greil, Johannes Gaenzer, Wolfgang Eisterer, Joerg Tschmelitsch, Felix Keil, Hellmut Samonigg, August Zabernigg, Franz Schmid, Günther Steger, Robert Steinacher, Johannes Andel, Björn Jagdt, Alois Lang, Michael Fridrik, Reinhold Függer, Friedrich Hofbauer, Ewald Woell, Dietmar Geissler, Alfred Lenauer, Manfred Prager, Geert D'Haens, Gauthier Demolin, Joseph Kerger, Guido Deboever, Gilbert Ghillebert, Marc Polus, Eric Van Cutsem, Hassan Rezaie Kalantari, Thierry Delaunoit, Jean Charles Goeminne, Marc Peeters, Philippe Vergauwe, Ghislain Houbiers, Yves Humblet, Jos Janssens, Dirk Schrijvers, Erik Vanderstraeten, Jean-Luc Van Laethem, Jan Vermorken, Daniel Van Daele, Michel Ferrante, Frederic Forget, Alain Hendlisz, Mette Yilmaz, Svend Erik Nielsen, Lene Vestermark, Jim Larsen, Mohamed-Ayman Zawadi, Olivier Bouche, Laurent Mineur, Jaafar Bennouna-Louridi, Louis Marie Dourthe, Marc Ychou, Eveline Boucher, Julien Taieb, Denis Pezet, Francoise Desseigne, Michel Ducreux, Patrick Texereau, Laurent Miglianico, Philippe Rougier, Serge Fratte, Charles-Briac Levache, Yacine Merrouche, Stephen Ellis, Christophe Locher, Jean-Francois Ramee, Claire Garnier, Frederic Viret, Bruno Chauffert, Isabelle Cojean-Zelek, Pierre Michel, Cedric Lecaille, Christian Borel, Jean-Francois Seitz, Denis Smith, Catherine Lombard-Bohas, Thierry Andre, Jean-Marc Gornet, Francine Fein, Marie-Aude Coulon-Sfairi, Marie-Christine Kaminsky, Jean-Paul Lagasse, Dominique Luet, Pierre-Luc Etienne, Mohamed Gasmi, Andre Vanoli, Suzanne Nguyen, Thomas Aparicio, Hervé Perrier, Noel Stremsdoerfer, Philippe Laplaige, Dominique Arsene, Dominique Auby, Laurent Bedenne, Romain Coriat, Bernard Denis, Patrick Geoffroy, Gilles Piot, Yves Becouarn, Gilbert Bordes, Gael Deplanque, Olivier Dupuis, Frederic Fruge, Rosine Guimbaud, Thierry Lecomte, Gérard Lledo, Iradej Sobhani, Amani Asnacios, Ahmed Azzedine, Christophe Desauw, Marie-Pierre Galais, Dany Gargot, You-Heng Lam, Abakar Abakar-Mahamat, Jean-Francois Berdah, Sylviane Catteau, Marie-Christine Clavero-Fabri, Jean-Francois Codoul, Jean-Louis Legoux, Denis Goldfain, Pierre Guichard, Denis Pere Verge, Jocelyne Provencal, Bruno Vedrenne, Catherine Brezault-Bonnet, Denis Cleau, Jean-Paul Desir, David Fallik, Bruno Garcia, Marie-Hélène Gaspard, Dominique Genet, Johannes Hartwig, Yves Krummel, Tamara Matysiak Budnik, Vanessa Palascak-Juif, Harizo Randrianarivelo, Yves Rinaldi, Albert Aleba, Ariane Darut-Jouve, Aimery de Gramont, Herve Hamon, Frederic Wendehenne, Axel Matzdorff, Michael Konrad Stahl, Wolfgang Schepp, Martin Burk, Lothar Mueller, Gunnar Folprecht, Michael Geissler, Luisa Mantovani-Loeffler, Thomas Hoehler, Walter Asperger, Hendrik Kroening, Ludwig Fischer von Weikersthal, Stefan Fuxius, Matthias Groschek, Johannes Meiler, Tanja Trarbach, Jacqueline Rauh, Nicolas Ziegenhagen, Albrecht Kretzschmar, Ullrich Graeven, Arnd Nusch, Goetz von Wichert, Ralf-Dieter Hofheinz, Gerhard Kleber, Karl-Heinz Schmidt, Ursula Vehling-Kaiser, Claudia Baum, Jochen Schuette, Georg Martin Haag, Wilhelm Holtkamp, Jochen Potenberg, Tobias Reiber, Georg Schliesser, Hans-Joachim Schmoll, Wolfgang Schneider-Kappus, Wolfgang Abenhardt, Claudio Denzlinger, Jan Henning, Bartscht Marxsen, Hans Guenter Derigs, Helmut Lambertz, Ingulf Becker-Boost, Karel Caca, Christian Constantin, Thomas Decker, Henning Eschenburg, Sigrun Gabius, Holger Hebart, Albrecht Hoffmeister, Heinz-August Horst, Stephan Kremers, Malte Leithaeuser, Sebastian Mueller, Siegfried Wagner, Severin Daum, Frank Schlegel, Martina Stauch, Volker Heinemann, Evaristo Maiello, Luciano Latini, Alberto Zaniboni, Dino Amadori, Giuseppe Aprile, Sandro Barni, Rodolfo Mattioli, Andrea Martoni, Rodolfo Passalacqua, Mario Nicolini, Enzo Pasquini, Carla Rabbi, Enrico Aitini, Alberto Ravaioli, Carlo Barone, Guido Biasco, Stefano Tamberi, Angelo Gambi, Claudio Verusio, Marina Marzola, Giorgio Lelli, Corrado Boni, Stefano Cascinu, Paolo Bidoli, Massimo Vaghi, Giorgio Cruciani, Francesco Di Costanzo, Alberto Sobrero, Enrico Mini, Roberto Petrioli, Massimo Aglietta, Oscar Alabiso, Federico Capuzzo, Alfredo Falcone, Domenico Cristi Corsi, Roberto Labianca, Stefania Salvagni, Silvana Chiara, Libero Ciuffreda, Francesco Ferraù, Francesco Giuliani, Sara Lonardi, Nicola Gebbia, Giovanni Mantovani, Evaristo Sanches, Juan Carlos Mellidez, Pedro Santos, Joao Freire, Cristina Sarmento, Luis Costa, Antonio Moreira Pinto, Sergio Barroso, Jorge Espirito Santo, Fátima Guedes, Amélia Monteiro, Anabela Sa, Irene Furtado, Ramon Salazar, Enrique Aranda Aguilar, Fernando Rivera Herrero, Josep Tabernero, Javier Sastre Valera, Manuel Valladares Ayerbes, Jaime Feliu Batlle, Silvia Gil, Albert Abad Esteve, Carlos Garcia-Giron, Guillermo Lopez Vivanco, Antonia Salud Salvia, Vicente Alonso Orduña, Ruth Vera Garcia, Javier Gallego, Bartomeu Massuti Sureda, Jordi Remon, Maria Jose Safont Aguilera, Luis Cirera Nogueras, Bernado Queralt Merino, Cristina Gravalos Castro, Purificacion Martinez de Prado, Carlos Pijaume Pericay, Manuel Constenla Figueiras, Inmaculada Guasch Jordan, Maria Jose Gome Reina, Amelia Lopez-Ladron Garcia, Antonio Arrivi Garcia-Ramos, Andres Cervantes, Carlos Fernandez Martos, Eugenio Marcuello Gaspar, Ines Cabezas Montero, Pilar Escudero Emperador, Ana Leon Carbonero, Manuel Gallen Castillo, Teresa Garcia Garcia, Jose Garcia Lopez, Encarnacion Gonzalez Flores, Monica Guillot Morales, Marta Llanos Muñoz, Ana López Martín, Joan Maurel, Juan Carlos Camara, Rosario Dueñas Garcia, Mercedes Salgado, Isabel Hernandez Busquier, Teresa Checa Ruiz, Adelaida Lacasta Muñoa, Miquel Nogue Aliguer, Amalia Velasco Ortiz de Taranco, Miguel Mendez Ureña, Ferran Losa Gaspa, Jose Juan Ponce, Carlos Bosch Roig, Pedro Valero Jimenez, Antonio Galan Brotons, Santiago Albiol Rodriguez, Jose Ales Martinez, Liliana Canosa Ruiz, Margarita Centelles Ruiz, John Bridgewater, Rob Glynne-Jones, Saad Tahir, Tamas Hickish, Jim Cassidy, Leslie Samuel
European Journal of Cancer, 2017
The meaningness of colon cancer sidedness
Alain Hendlisz
Current Opinion in Oncology, 2017
Tackling immunomonitoring in gastrointestinal cancer
Maëlle Anciaux, Caroline Vandeputte, Alain Hendlisz
Current Opinion in Oncology, 2017
Dyspnea and cardia cancer, an unusual etiology
Revue Medicale De Bruxelles, 2017
Systematic review and meta-analysis of local resection or transanal endoscopic microsurgery versus radical resection in stage i rectal cancer: A real standard?
Geneviève Veereman, Joan Vlayen, Jo Robays, Nicolas Fairon, Sabine Stordeur, Christian Rolfo, Didier Bielen, Alain Bols, Pieter Demetter, André D’hoore, Karin Haustermans, Alain Hendlisz, Arnaud Lemmers, Daniel Leonard, Freddy Penninckx, Eric Van Cutsem, Marc Peeters
Critical Reviews in Oncology Hematology, 2017
Accuracy of FDG-PET/CT in colorectal peritoneal carcinomatosis: Potential tool for evaluation of chemotherapeutic response
GABRIEL LIBERALE, CÉLINE LECOCQ, CAMILO GARCIA, KRISTOF MUYLLE, ANGÉLIQUE COVAS, AMÉLIE DELEPORTE, ALAIN HENDLISZ, FIKRI BOUAZZA, ISSAM EL NAKADI, PATRICK FLAMEN
Anticancer Research, 2017
Salvage esophagectomy after failure of definitive radiochemotherapy for esophageal cancer
Eleonora Farinella, Adonis Safar, Haydar A. Nasser, Fikri Bouazza, Gabriele Liberale, Marianne Paesmans, Raphael Marechal, Jean-Luc Van Laethem, Alain Hendlisz, Paul VanHoutte, Issam El Nakadi
Journal of Surgical Oncology, 2016
Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer
Erwin Woff, Alain Hendlisz, Camilo Garcia, Amelie Deleporte, Thierry Delaunoit, Raphaël Maréchal, Stéphane Holbrechts, Marc Van den Eynde, Gauthier Demolin, Irina Vierasu, Renaud Lhommel, Namur Gauthier, Thomas Guiot, Lieveke Ameye, Patrick Flamen
European Journal of Nuclear Medicine and Molecular Imaging, 2016
Too little benefit for too much toxicity: Rethinking the adjuvant development model in colon cancer
Alain Hendlisz, Harry Bleiberg
Current Opinion in Oncology, 2016
Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer
Alexander Hamm, Hans Prenen, Wouter Van Delm, Mario Di Matteo, Mathias Wenes, Estelle Delamarre, Thomas Schmidt, Jürgen Weitz, Roberta Sarmiento, Angelo Dezi, Giampietro Gasparini, Françoise Rothé, Robin Schmitz, André D'Hoore, Hannes Iserentant, Alain Hendlisz, Massimiliano Mazzone
Gut, 2016
Missing metastases as a model to challenge current therapeutic algorithms in colorectal liver metastases
Valerio Lucidi, Alain Hendlisz, Jean-Luc Van Laethem, Vincent Donckier
World Journal of Gastroenterology, 2016
In Deciphering the Future of Adjuvant Treatment in Colon Cancer, the Journey Matters More than the Achievements
Alain Hendlisz, Francesco Puleo, Amelie Deleporte, Leila Shaza, Nicolas Charette
Current Colorectal Cancer Reports, 2016
Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: Proof of concept
Minerva Chirurgica, 2016
Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
E Elez, A Hendlisz, T Delaunoit, J Sastre, A Cervantes, R Varea, G Chao, J Wallin, J Tabernero
British Journal of Cancer, 2016
A first-in-human phase i and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours
B. Venugopal, A. Awada, T. R. J. Evans, S. Dueland, A. Hendlisz, W. Rasch, K. Hernes, S. Hagen, S. Aamdal
Cancer Chemotherapy and Pharmacology, 2015
The prognostic significance of metabolic response heterogeneity in metastatic colorectal cancer
Alain Hendlisz, Amelie Deleporte, Thierry Delaunoit, Raphaël Maréchal, Marc Peeters, Stéphane Holbrechts, Marc Van den Eynde, Ghislain Houbiers, Bertrand Filleul, Jean-Luc Van Laethem, Sarah Ceyssens, Anna-Maria Barbuto, Renaud Lhommel, Gauthier Demolin, Camilo Garcia, Hazem El Mansy, Lieveke Ameye, Michel Moreau, Thomas Guiot, Marianne Paesmans, Martine Piccart, Patrick Flamen
Plos One, 2015
Colorectal cancer: Ten years of illusion of progress but advances are on the horizon
Revue Medicale De Bruxelles, 2015
Radioembolisation and portal vein embolization before resection of large hepatocellular carcinoma
Fikri Bouazza
World Journal of Gastroenterology, 2015
Evolution in the therapeutic strategy of localized resectable pancreatic ductal adenocarcinoma
Revue Medicale Suisse, 2015
Of art and science: Is personalized medicine getting personal enough?
Alain Hendlisz
Current Opinion in Oncology, 2015
Y90 radioembolization of colorectal cancer liver metastases: Response assessment by contrast-enhanced computed tomography with or without PET-CT guidance
Michael Vouche, Riad Salem, Frank H. Miller, Marc Lemort, Bruno Vanderlinden, Daniel De Becker, Alain Hendlisz, Patrick Flamen
Clinical Imaging, 2015
Chemotherapy treatment patterns and neutropenia management in gastric cancer
Ewa Kalinka-Warzocha, Javier Gallego Plazas, Laurent Mineur, Tomas Salek, Alain Hendlisz, Lucy DeCosta, Florian D. Vogl, Rodolfo Passalacqua
Gastric Cancer, 2015
Pooled analysis of the surgical treatment for colorectal cancer liver metastases
G. Veereman, J. Robays, L. Verleye, R. Leroy, C. Rolfo, E. Van Cutsem, D. Bielen, W. Ceelen, E. Danse, M. De Man, P. Demetter, P. Flamen, A. Hendlisz, I. Sinapi, D. Vanbeckevoort, D. Ysebaert, M. Peeters
Critical Reviews in Oncology Hematology, 2015
Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study [BMC Cancer, 13, (2013), 190]
Alain Hendlisz, Vassilis Golfinopoulos, Amelie Deleporte, Marianne Paesmans, Hazem El Mansy, Camilo Garcia, Marc Peeters, Lieven Annemans, Caroline Vandeputte, Marion Maetens, Marc Van den Eynde, Raphaël Maréchal, Ivan Borbath, Damien Dresse, Ghislain Houbiers, Michael Fried, Ahmad Awada, Martine Piccart, Jean-Luc Van Laethem, Patrick Flamen
BMC Cancer, 2015
Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol
Alain Hendlisz, Amélie Deleporte, Caroline Vandeputte, Nicolas Charette, Marianne Paesmans, Thomas Guiot, Camilo Garcia, Patrick Flamen
BMJ Open, 2015
Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: The CORIOLAN study
Amelie Deleporte, Marianne Paesmans, Camilo Garcia, Caroline Vandeputte, Marc Lemort, Jean-Luc Engelholm, Frederic Hoerner, Philippe Aftimos, Ahmad Awada, Nicolas Charette, Godelieve Machiels, Martine Piccart, Patrick Flamen, Alain Hendlisz
BMC Cancer, 2014
Erratum: Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres (Physics in Medicine and Biology (2008) 53 (6591-603))
Patrick Flamen, Bruno Vanderlinden, Philippe Delatte, Ghanem Ghanem, Lieveke Ameye, Marc Van Den Eynde, Alain Hendlisz
Physics in Medicine and Biology, 2014
In times of crisis, go liquid!
Alain Hendlisz, Amélie Deleporte, Caroline Vandeputte
Current Opinion in Oncology, 2014
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)
Franck Bonnetain, Bert Bonsing, Thierry Conroy, Adelaide Dousseau, Bengt Glimelius, Karin Haustermans, François Lacaine, Jean Luc Van Laethem, Thomas Aparicio, Daniela Aust, Claudio Bassi, Virginie Berger, Emmanuel Chamorey, Benoist Chibaudel, Laeticia Dahan, Aimery De Gramont, Jean Robert Delpero, Christos Dervenis, Michel Ducreux, Jocelyn Gal, Erich Gerber, Paula Ghaneh, Pascal Hammel, Alain Hendlisz, Valérie Jooste, Roberto Labianca, Aurelien Latouche, Manfred Lutz, Teresa Macarulla, David Malka, Muriel Mauer, Emmanuel Mitry, John Neoptolemos, Patrick Pessaux, Alain Sauvanet, Josep Tabernero, Julien Taieb, Geertjan van Tienhoven, Sophie Gourgou-Bourgade, Carine Bellera, Simone Mathoulin-Pélissier, Laurence Collette
European Journal of Cancer, 2014
Phase i study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors
F. E. Stuurman, E. E. Voest, A. Awada, P. O. Witteveen, T. Bergeland, P.-A. Hals, W. Rasch, J. H. M. Schellens, A. Hendlisz
Investigational New Drugs, 2013
Editorial introductions
Klastersky, Jean, Jonathan C. Trent, Alain Hendlisz
Current Opinion in Oncology, 2013
Academic versus industry-driven research in upper gastrointestinal cancer: Sinners and saints
Alain Hendlisz, Nicolas Charette, Ahmad Awada, Amélie Deleporte
Current Opinion in Oncology, 2013
Phase i study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
A. H. Awada, H. Dumez, A. Hendlisz, P. Wolter, T. Besse-Hammer, M. Uttenreuther-Fischer, P. Stopfer, F. Fleischer, M. Piccart, P. Schöffski
Investigational New Drugs, 2013
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study
Alain Hendlisz, Vassilis Golfinopoulos, Amelie Deleporte, Marianne Paesmans, Hazem El Mansy, Camilo Garcia, Marc Peeters, Lieven Annemans, Caroline Vandeputte, Marion Maetens, Ivan Borbath, Damien Dresse, Ghislain Houbiers, Michael Fried, Ahmad Awada, Martine Piccart, Jean-Luc Van Laethem, Patrick Flamen
BMC Cancer, 2013
Comparison of PET metabolic indices for the early assessment of tumour response in metastatic colorectal cancer patients treated by polychemotherapy
Jacques-Antoine Maisonobe, Camilo A. Garcia, Hatem Necib, Bruno Vanderlinden, Alain Hendlisz, Patrick Flamen, Irène Buvat
European Journal of Nuclear Medicine and Molecular Imaging, 2013
Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer
Irène Buvat, Hatem Necib, Camilo Garcia, Antoine Wagner, Bruno Vanderlinden, Patrick Emonts, Alain Hendlisz, Patrick Flamen
European Journal of Nuclear Medicine and Molecular Imaging, 2012
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: The randomized EVEREST study
Eric Van Cutsem, Sabine Tejpar, Dirk Vanbeckevoort, Marc Peeters, Yves Humblet, Hans Gelderblom, Jan B. Vermorken, Frederic Viret, Bengt Glimelius, Elisa Gallerani, Alain Hendlisz, Annemieke Cats, Markus Moehler, Xavier Sagaert, Soetkin Vlassak, Michael Schlichting, Fortunato Ciardiello
Journal of Clinical Oncology, 2012
Selective internal radiation therapy simulation using 99mTc-labelled macroaggregates of albumin and SPECT-CT
Patrick Flamen, Alain Hendlisz, Bruno Vanderlinden
European Journal of Cancer Supplement, 2012
The confusion around neuroendocrine tumors
Alain Hendlisz, Amélie Deleporte
Current Opinion in Oncology, 2012
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy
A. Hendlisz, V. Golfinopoulos, C. Garcia, A. Covas, P. Emonts, L. Ameye, M. Paesmans, A. Deleporte, G. Machiels, E. Toussaint, B. Vanderlinden, A. Awada, M. Piccart, P. Flamen
Annals of Oncology, 2012
Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: A randomized multicentric phase II study
R. Maréchal, B. Vos, M. Polus, T. Delaunoit, M. Peeters, P. Demetter, A. Hendlisz, A. Demols, D. Franchimont, G. Verset, P. Van Houtte, J. Van de Stadt, J.L. Van Laethem
Annals of Oncology, 2012
Phase i trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours
Ahmad Awada, Alain Hendlisz, Olaf Christensen, Chetan D. Lathia, Sylvie Bartholomeus, Fabienne Lebrun, Dominique de Valeriola, Erich Brendel, Martin Radtke, Thierry Delaunoit, Martine Piccart-Gebhart, Thierry Gil
European Journal of Cancer, 2012
The relationship between heart rate variability and time-course of carcinoembryonic antigen in colorectal cancer
Charlotte Mouton, Alain Ronson, Darius Razavi, François Delhaye, Nina Kupper, Marianne Paesmans, Michel Moreau, Jean-Marie Nogaret, Alain Hendlisz, Yori Gidron
Autonomic Neuroscience Basic and Clinical, 2012
New strategies and designs in pancreatic cancer research: Consensus guidelines report from a European expert panel
J.-L. Van Laethem, C. Verslype, J.L. Iovanna, P. Michl, T. Conroy, C. Louvet, P. Hammel, E. Mitry, M. Ducreux, T. Maraculla, W. Uhl, G. Van Tienhoven, J.B. Bachet, R. Maréchal, A. Hendlisz, M. Bali, P. Demetter, F. Ulrich, D. Aust, J. Luttges, M. Peeters, M. Mauer, A. Roth, J.P. Neoptolemos, M. Lutz
Annals of Oncology, 2012
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: Results of a phase 1 trial
Ahmad Awada, Thierry Gil, Nicolas Whenham, Julie Van Hamme, Tatiana Besse-Hammer, Erich Brendel, Heinz Delesen, Miranda C. Joosten, Chetan D. Lathia, Bienvenu A. Loembé, Martine Piccart-Ghebart, Alain Hendlisz
Journal of Clinical Pharmacology, 2011
Progression-free survival ratio as end point for phase II trials in advanced solid tumors
Marc Buyse, Emmanuel Quinaux, Alain Hendlisz, Vassilis Golfinopoulos, Christophe Tournigand, Rosemarie Mick
Journal of Clinical Oncology, 2011
Detection and characterization of tumor changes in 18F-FDG PET patient monitoring using parametric imaging
Hatem Necib, Camilo Garcia, Antoine Wagner, Bruno Vanderlinden, Patrick Emonts, Alain Hendlisz, Patrick Flamen, Irène Buvat
Journal of Nuclear Medicine, 2011
Small cell carcinoma of the esophagus: A multicentre rare cancer network study
B. Vos, T. Rozema, R. C. Miller, A. Hendlisz, J. L. Van Laethem, K. Khanfir, D. C. Weber, I. El Nakadi, P. Van Houtte
Diseases of the Esophagus, 2011
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy
Alain Hendlisz, Marc Van den Eynde, Marc Peeters, Geert Maleux, Bieke Lambert, Jaarke Vannoote, Katrien De Keukeleire, Chris Verslype, Luc Defreyne, Eric Van Cutsem, Philippe Delatte, Thierry Delaunoit, Nicola Personeni, Marianne Paesmans, Jean-Luc Van Laethem, Patrick Flamen
Journal of Clinical Oncology, 2010
Current Opinion in Oncology: Editorial introductions
&NA;
Current Opinion in Oncology, 2010
A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients
Acta Gastro Enterologica Belgica, 2010
The unfulfilled promise of molecular diagnosis in colorectal cancer
Vassilis Golfinopoulos, Alain Hendlisz
Current Opinion in Oncology, 2010
State of the art: Radiolabeled microspheres treatment for liver malignancies
Amélie Deleporte, Patrick Flamen, Alain Hendlisz
Expert Opinion on Pharmacotherapy, 2010
Is tailored adjuvant treatment for colon cancer possible?
Marc Van den Eynde, Ahmad Awada, Alain Hendlisz
Clinical Colorectal Cancer, 2010
Editorial: Adjuvant trials design in colon cancer
Alain Hendlisz, Vassilis Golfinopoulos
Current Opinion in Oncology, 2009
Current Opinion in Oncology: Editorial introductions
Current Opinion in Oncology, 2009
Treatment of colorectal liver metastases: A review
M. Eynde, A. Hendlisz
Reviews on Recent Clinical Trials, 2009
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy
Marc Peeters, Salvatore Siena, Eric Van Cutsem, Alberto Sobrero, Alain Hendlisz, Stefano Cascinu, Haralabos Kalofonos, Giovanna Devercelli, Michael Wolf, Rafael G. Amado
Cancer, 2009
Therapeutic consequences of molecular biology advances in oncology
F Bauvet, A Awada, T Gil, A Hendlisz
Bulletin Du Cancer, 2009
Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: A prospective dose finding phase I-II study
S. Laurent, E. Monsaert, T. Boterberg, A. Demols, I. Borbath, M. Polus, A. Hendlisz, B. de Hemptinne, C. Mahin, P. Scalliet, J.-L. Van Laethem, M. Peeters
Annals of Oncology, 2009
The antiproliferative effect of somatostatin analogs: Clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours
Acta Gastro Enterologica Belgica, 2009
The potential role of targeted therapies in the management of neuroendocrine tumours
Acta Gastro Enterologica Belgica, 2009
Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: The end of a story?
Acta Gastro Enterologica Belgica, 2009
Diagnostic pitfalls in digestive neuroendocrine tumours
Acta Gastro Enterologica Belgica, 2009
Locoregional and radioisotopic targeted treatment of neuroendocrine tumours
Acta Gastro Enterologica Belgica, 2009
The role of surgery and transplantation in neuroendocrine tumours
Acta Gastro Enterologica Belgica, 2009
Carcinoid heart disease - A hidden complication of neuroendocrine tumours
Acta Gastro Enterologica Belgica, 2009
Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres
Patrick Flamen, Bruno Vanderlinden, Philippe Delatte, Ghanem Ghanem, Lieveke Ameye, Marc Van Den Eynde, Alain Hendlisz
Physics in Medicine and Biology, 2008
Management of cutaneous toxicities induced by epidermal growth factor receptor inhibitors: A review
Revue Medicale De Bruxelles, 2008
Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer
Raphaël Maréchal, Anne Demols, France Gay, Viviane de Maertelaer, Marianna Arvanitaki, Alain Hendlisz, Jean-Luc Van Laethem
Pancreas, 2008
Recommendations for general surgeons facing incidental peritoneal carcinomatosis of colorectal origin
G. Liberale, M. Van Den Eynde, A. Hendlisz, I. El Nakadi
European Journal of Surgical Oncology, 2008
Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres
Marc Van den Eynde, Patrick Flamen, Issam El Nakadi, Gabriel Liberale, Philippe Delatte, Denis Larsimont, Alain Hendlisz
Clinical Nuclear Medicine, 2008
Concomitant chemo-radiotherapy as standard therapy in limited-stage small-cell oesophageal cancer: A summary of 3 clinical cases and review of the literature
Acta Gastro Enterologica Belgica, 2008
Epidermoid carcinoma of the colon and rectum and paraneoplastic hypercalcemia
Acta Clinica Belgica, 2007
Editorial introductions
Klastersky, Jean, Von Mehren, Margaret, Hendlisz, Alain
Current Opinion in Oncology, 2007
A therapeutic approach to perianal extramammary Paget's disease: Topical imiquimod can be useful to prevent or defer surgery
Medical Science Monitor, 2007
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors
Dirk Strumberg, Jeffrey W. Clark, Ahmad Awada, Malcolm J. Moore, Heike Richly, Alain Hendlisz, Hal W. Hirte, Joseph P. Eder, Heinz-Josef Lenz, Brian Schwartz
Oncologist, 2007
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer
Eric Van Cutsem, Marc Peeters, Salvatore Siena, Yves Humblet, Alain Hendlisz, Bart Neyns, Jean-Luc Canon, Jean-Luc Van Laethem, Joan Maurel, Gary Richardson, Michael Wolf, Rafael G. Amado
Journal of Clinical Oncology, 2007
Don't believe... check!!
Alain Hendlisz
Current Opinion in Oncology, 2007
Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer
R. Maréchal, A. Demols, F. Gay, V. De Maertelaere, M. Arvanitaki, A. Hendlisz, J.L. Van Laethem
Oncology, 2007
Efficacy and side effects of target biological therapies
A. Awada, A. Hendlisz, M.-J. Piccart-Gebhart
Oncologie, 2006
Screening colorectal cancer: The selection of patients at risk
Revue Medicale De Bruxelles, 2006
Editorial introductions
Klastersky, Jean, Von Mehren, Margaret, Hendlisz, Alain
Current Opinion in Oncology, 2006
Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: A phase II study
A Demols, M Peeters, M Polus, R Marechal, F Gay, E Monsaert, A Hendlisz, J L Van Laethem
British Journal of Cancer, 2006
Hepatic intra-arterial injection of Yttrium-loaded microspheres for Liver Metastasis secondary to colorectal cancer: Best soups are sometimes made from old recipies
Acta Gastro Enterologica Belgica, 2006
Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases
Nathalie Baize, Béatrice Gerard, Harry Bleiberg, François Caroli-Bosc, Frédéric Berthier, Hughes Legendre, Jean-Claude Pector, Alain Hendlisz
Gastroenterologie Clinique Et Biologique, 2006
Colorectal cancer (CRC) screening using sigmoidoscopy followed by colonoscopy: A feasibility and efficacy study on a cancer institute based population
H. Bleiberg, P. Autier, F. Huet, A.M. Schrauwen, E. Staquet, T. Delaunoit, A. Hendlisz, C. Wyns, J.M. Panzer, B. Caucheteur, P. Eisendrath, A. Grivegnée
Annals of Oncology, 2006
Molecular medicine: Are we, clinicians, becoming old-fashioned?
Alain Hendlisz
Current Opinion in Oncology, 2005
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
A Awada, A Hendlisz, T Gil, S Bartholomeus, M Mano, D de Valeriola, D Strumberg, E Brendel, C G Haase, B Schwartz, M Piccart
British Journal of Cancer, 2005
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer
N PERSONENI, A HENDLISZ, J GALLEZ, M GALDON, D LARSIMONT, J VANLAETHEM, N NAGY, M BARETTE, M PAESMANS, F CARDOSO
Seminars in Oncology, 2005
Oral fluoropyrimidines in colorectal cancer: A door open to the future?
Acta Gastro Enterologica Belgica, 2004
Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: An easy-to-use and well-tolerated combination
T. Delaunoit, R. Maréchal, A. Hendlisz, P. Eisendrath, H. Legendre, J. C. Pector, D. De Becker, H. Bleiberg
Anti Cancer Drugs, 2004
New anticancer agents and therapeutic strategies in development for solid cancers: A clinical perspective
Ahmad Awada, Max Mano, Alain Hendlisz, Martine Piccart
Expert Review of Anticancer Therapy, 2004
Prognostic stratification of Dukes B colon cancer by a neoglycoprotein.
Hugues Legendre, Christine Decaestecker, Max Gbenou, Nathalie Nagy, Alain Hendlisz, Sabine André, Jean-Claude Pector, Robert Kiss, Hans-Joachim Gabius
International Journal of Oncology, 2004
Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers
Hugues Legendre, Christine Decaestecker, Nathalie Nagy, Alain Hendlisz, Max-Peter Schüring, Isabelle Salmon, Hans-Joachim Gabius, Jean-Claude Pector, Robert Kiss
Modern Pathology, 2003
Advanced colorectal cancer treatment in Europe: What have we achieved?
Harry Bleiberg, Alain Hendlisz
Anti Cancer Drugs, 2002
A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas
F.X Caroli-Bosc, J.L Van Laethem, P Michel, F Gay, A Hendlisz, F Forget, H Bleiberg
European Journal of Cancer, 2001
Oxaliplatin combined to 5-fluorouracil and folinic acid: An effective therapy in patients with advanced colorectal cancer
B Gerard, H Bleiberg, D Van Daele, Th Gil, A Hendlisz, A Di Leo, B Fernez, S Brienza
Anti Cancer Drugs, 1998
Importance of radiotherapy for gastric cancer
Bulletin Du Cancer, 1997
Non-surgical treatment of cancer of the pancreas
Journal De Chirurgie, 1997
Surveillance postopératoire des cancers colo-rectaux
Revue Du Praticien, 1996
Diagnosis and Treatment of Gastric Cancer
Alain Hendlisz, Harry Bleiberg
Drugs, 1995
Spinal epidural abscess after endoscopic treatment for chronic pancreatitis
Alain Hendlisz, Françoise Rypens, France Gay, André Vancossum, Michel Cremer
Pancreas, 1995

Alain Hendlisz

RESEARCH INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS